Live
- Nani unveils ‘MM 2’ title & first look
- Will challenge bail granted to actor Darshan in fan murder case in SC: Bengaluru Police Commissioner
- Chandrahass Launches Maruti Suzuki Dzire Through PJ Productions in Tolichowki Showroom
- Police case against farmers for tilling land claimed by Waqf Board in Karnataka
- Commendable move: Sandeep Dikshit on renaming Sarai Kale Khan ISBT chowk after Birsa Munda
- MahaYuti will come back to power with a thumping majority despite Oppn's tirade: Eknath Shinde
- ‘Hanging up my racquet. Thank you’ - India’s Prajnesh Gunneswaran retires from professional tennis
- Pawan Kalyan to Campaign for NDA Alliance in Maharashtra
- Eight killed, five injured in Nepal's traffic accident
- Technical snag grounds PM Modi's aircraft in Jharkhand
Suven gets patents on neurological molecule
Suven Life Sciences has been granted a patent each from Hong Kong and the US and two from India for treatment of disorders associated with neurodegenerative diseases.
Hyderabad: Suven Life Sciences has been granted a patent each from Hong Kong and the US and two from India for treatment of disorders associated with neurodegenerative diseases.
These patents are valid till 2032, 2030 and 2034 respectively, according to a communique the company said in a BSE filing. The market capitalisation of the company surged by Rs94 crore to Rs2,522.10 crore.
Suven Life CEO Venkat Jasti said: “We’re very pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS (central nervous system) arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally.”
The granted claims of the patents are being developed as therapeutic agents and are useful in the treatment of cognitive impairment.
